Loading...
The concept of personalized or precision medicine has been an aspirational mantra for oncologists for many years. The notion that we could tailor therapy to the specific biology of each tumor held the promise of greater anti-tumor efficacy than the standard “one-size-fits-all” approach. With commercial enterprises available to analyze an individual tumor for specific mutations, the concept of precision medicine is closer to reality in oncology — or is it?
With the aim of providing targeted therapy matched to a tumor's genomic alterations, French investigators conducted a multicenter molecular screening trial in which 407 biopsy samples from 423 patients with metastatic disease were assessed using comparative genomic hybridization array (67% …